Creatine phosphate: pharmacological and clinical perspectives.

Since the 1970s, extensive experimental and clinical research has demonstrated that relevant reductions of creatine phosphate (CrP) or phosphocreatine availability occur in a wide spectrum of pathophysiological situations. A decrease in intracellular concentrations of creatine (Cr) and CrP results in a hypodynamic state of cardiac and skeletal muscle pathology. Many experimental and clinical studies have evaluated the possibility to improve cardiac and skeletal muscle performance by exogenous administration of CrP.

St. Thomas' Hospital cardioplegia: enhanced protection with exogenous creatine phosphate.

Background: Experimentally, creatine phosphate (CP) improves postischemic recovery of function and reduces postischemic arrhythmias.

Methods: We studied 50 patients undergoing valve replacement. They were randomized into either a control group, who received St.

[The efficacy of creatine phosphate in the treatment of patients with heart failure. Its echographic evaluation after acute and protracted treatment].

The hemodynamic effects of acute and long-term administration of creatine phosphate were studied in 23 patients with heart failure (NYHA classes II and III) under stabilized treatment. Acute creatine phosphate (5 g i.v.

[Molecular and cellular aspects of the cardioprotective mechanism of phosphocreatine].

The present state of investigations on molecular and cellular mechanisms of cardioprotective effects of phosphocreatine (PCr) is reviewed. The protective effect of PCr is manifested as significant improvement of heart contractile function recovery, lowering of diastolic pressure elevation and myocardial enzymes release during postischemic reperfusion as well as better preservation of high energy phosphates in comparison with control. Data from multidisciplinary studies using physico-chemical, physiological, pharmacological etc.

Effects of doxefazepam on normal sleep. An EEG and neuropsychological study.

The effects on sleep of a putative hypnotic, benzodiazepine (doxefazepam), were studied in 7 healthy volunteers. Subjects were administered placebo or the active compound at 10-, 20-, and 40-mg oral dose prior to 13 consecutive nights during which they slept in the EEG laboratory. Full-night EEG recordings were obtained, and the hypnogram was determined.

Prolactin secretion during reserpine and syrosingopine treatment.

In 20 mild hypertensive women, reserpine induced a significant increase in mean plasma PRL, both under basal conditions (from 6.6 +/- 0.9 to 17.

Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings.

The sedative-hypnotic effects of a new benzodiazepine, 1-(2-hydroxyethyl)-3-hydroxy-7-chloro-1,3-dihydro-5-(o-fluorophenyl)-2H-1,4-benzodiazepin-2-one (SAS 643), were compared with those of flurazepam in mice and rats as well as in a double-blind clinical trial. It was found that SAS 643 has a potency 2--4 times greater than that of flurazepam while it is about one half less toxic than the latter drug. The results of the clinical trial confirm the greater activity of SAS 643 and indicate that the new benzodiazepine causes a significantly less amount of hangover than flurazepam.